Strengthen the construction of channels and improve the brand image Hantai Tire has been making efforts in 2014 China's auto aftermarket
It is reported that by the end of 2013, the total number of Hankook Tire 's branded service franchises in China had reached nearly 1900. Hankook Tire stated that with the rapid increase in the number of vehicle ownership in China and the increasing demand for replacement, China’s auto aftermarket will usher in an unprecedented opportunity in 2014.
It is reported that through the improvement of product structure, increase of sales channels and improvement of production capacity, the current Chinese market has become Hankook Tire’s largest overseas market.
In 2013, Hankook Tire's sales in China achieved double-digit growth. Hantai Tire said that in 2014, it will strengthen the construction of domestic retail channels, continuously improve service technology, and strive to meet the needs of China's huge automotive aftermarket with a globally unified high-quality network construction standard.
In addition, while strengthening the construction of retail channels, in 2014, Hankook Tire will continue to strengthen the image of the brand's high-end equipment, using high-performance tires as the engine, and exerting force on the Chinese automotive aftermarket.
According to reports, the second phase of Hankook Tire's Chongqing plant will be completed this year, which will further increase Hankook Tire's production capacity in China.
Macitentan is an orally available dual endothelin receptor (ETR) antagonist with potential antihypertensive and antineoplastic activity. Upon administration, macitentan and its metabolites block the binding of endothelin isoform 1 (ET-1) to type-A and type-B ETR on both the tumor cells and the endothelial cells in the tumor vasculature. This prevents ET-1 mediated signaling transduction which may decrease tumor cell proliferation, progression, and angiogenesis in tumor tissue. ET-1, a potent vasoconstrictor that plays an important role in inflammation and tissue repair, is, together with its receptors, overexpressed varyingly in many tumor cell types.
Macitentan is an endothelin receptor antagonist that is used in the therapy of pulmonary arterial hypertension (PAH). Macitentan has been associated with a low rate of serum enzyme elevations during therapy, but has yet to be implicated in cases of clinically apparent acute liver injury.
Macitentan Api,Macitentan Cas 441798-33-0,Macitentan Actelion-1 Opsumit,Macitentan Api Project Actelion-1
 Shandong Haohong Biotechnology Co., Ltd. , https://www.haohongpharma.com